ROSA Scientific

What ROSA Scientific does

ROSA Scientific (legal entity: G1 Sciences, LLC) is a Princeton, NJ-based biotechnology company founded in February 2018 that develops a proteogenomics diagnostics platform combining massively parallel analyte detection (up to 500 analytes simultaneously), computational biology, and next-generation sequencing. The company's core technology enables simultaneous detection of carbohydrates, proteins, and glycoproteins at extremely low concentrations with minimal sample preparation, supported by a proprietary Disease Proteomics Database and an antibody repository. Its primary commercial offering, ROSA Fertility NICS (Non-Invasive Chromosomal Screening), provides preimplantation genetic testing for aneuploidy using spent culture media without embryo biopsy, powered by Avrio Genetics' MALBAC amplification technology and offered through CLIA-certified labs with 24-hour to 7-day turnaround.

The company generates revenue through multiple service streams: CLIA-certified NICS laboratory testing for fertility clinics, full-stack companion diagnostics development for pharmaceutical and biotech clients, FDA regulatory consulting, antibody development services, and co-development partnerships. Its customer base spans fertility clinics (primary), pharmaceutical and biotech firms requiring companion diagnostics, and academic research institutions. Manufacturing is handled through a partnership with Ubio in India (ISO 13485:2016 certified, CDSCO-approved), and the company holds a granted US patent (February 2019) on its multiplexed analyte detection method. Distribution is direct B2B via a sales line (+1 202-780-ROSA) with no public pricing disclosed. Strategic backing includes HoMu Ventures (joined June 2020) and an affiliate relationship with Phosphorus (FDA-approved at-home SARS-CoV-2 PCR test).

Name

ROSA Scientific

Legal name

G1 Sciences, LLC

Website

https://rosascientific.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

ROSA Scientific is a Princeton-based biotech company developing a proteogenomics diagnostics platform that performs massively parallel analyte detection, serving fertility clinics with non-invasive chromosomal screening and pharmaceutical clients with companion diagnostics development services.

Ownership category

akta.pro rank

Product category

Companion Diagnostics Development Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)

akta.pro secondary industries

Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Genetic & Prenatal Testing Laboratories (HLAFAMAH), Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ), Proteomics & Biomarker Analytical Testing (HLAGADAG)

Keywords

• Diagnostic development platform
• Companion diagnostics services
• Non-invasive chromosomal screening
• Proteogenomics biomarker discovery
• Clinical laboratory testing

Headquarters

HQ city

Princeton

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Diagnostic Development Services: Full-stack IVD product development services including feasibility, discovery, and clinical validation of proteomic signatures for companion diagnostics, in accordance with US FDA Design Control and CE-IVD requirements.
2. Laboratory Testing Services (NICS): CLIA-certified laboratory providing Non-Invasive Chromosomal Screening (NICS) testing for fertility clinics. Turnaround time between 24 hours and 7 days. No batching requirements.
3. Regulatory Consulting: FDA consultation services for pre-market strategies, clinical investigations, review and approval pathways, NDAs, 510(k)s, de novo requests, PMAs, and post-marketing compliance.
4. Antibody Development Services: High quality monoclonal and polyclonal antibody development services for research and diagnostic applications.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

Core offering

ROSA Scientific develops a proprietary on-demand diagnostics platform built on a proteogenomics approach that combines massively parallel analyte detection, computational biology, and next-generation sequencing to enable rapid diagnostic development and biomarker discovery for complex diseases. The company markets the ROSA Fertility NICS laboratory service for non-invasive preimplantation genetic testing in IVF, delivers companion diagnostics development and regulatory consulting, and offers COVID-19 pooled testing and a non-invasive AMH test. Underlying capabilities include a disease proteomics database, a proprietary antibody repository, machine-learning-driven biomarker discovery, and Smart Test colorimetry enhancement technology for paper-based immunoassays.

Product overview

ROSA Scientific is a diagnostic development company built on a novel proteogenomics platform. The core offering consists of the ROSA On-Demand Diagnostics Platform, which provides a capital-efficient process for developing diagnostics through stage-gating, an antibody core, and massively parallel analyte detection (up to 500 analytes simultaneously). The company offers specific products including ROSA Fertility NICS for non-invasive chromosomal screening in IVF, the Smart Tests (Colorimetry) module for quantitating paper-based immunoassays, COVID-19 pooled testing, and a non-invasive AMH test. Platform features include a disease proteomics database and antibody repository. The company also provides regulatory and manufacturing services through ISO 13485:2016 certified partners.

Differentiator

Problem solved

Functional benefit

Products and services

• ROSA On-Demand Diagnostics Platform A diagnostic development platform that addresses cost, scalability, and throughput limitations of present diagnostic development processes through a stage-gated, capital-efficient process incorporating an antibody core, massively parallel analyte detection, and computational biology for scalable development. Targeted at pharmaceutical, biotech, biologics, and medical device organizations building companion diagnostics.
• ROSA Fertility NICS (Non-Invasive Chromosomal Screening) Best-in-class preimplantation genetic testing for aneuploidy (PGT-A) using only spent culture media, with no embryo biopsy required. Uses MALBAC amplification and Next Generation Sequencing to detect aneuploidy, partial (segmental) aneuploidy, polyploidies, and mosaicism, with 24-hour to 7-day turnaround and no batching requirements. Available to fertility clinics of any size, from 1 embryo to 100.
• COVID-19 Pooled Testing Pooling method for SARS-CoV-2 detection that achieves a 90% reduction in testing cost per patient in low-prevalence communities by combining samples and using RT-PCR technology adapted to allow pooled testing while maintaining gold-standard accuracy.
• Non-Invasive AMH Test Non-invasive fertility test for Anti-Müllerian Hormone (AMH) that measures fertility hormone from human hair samples, enabling assessment of ovarian reserve without blood draw. Developed by co-founder Sarthak Sawarkar and accepted by ESHRE.
• Companion Diagnostics Development Full-stack IVD product development services including feasibility, clinical-care pathway evaluation, discovery, and clinical validation of proteomic signatures, delivered in accordance with US FDA Design Control and CE-IVD requirements for pharmaceutical, biotech, and medical device customers.
• Regulatory Services FDA consultation services including clinical development, marketing authorization strategies, pre-market strategies, product development, clinical investigations, and post-marketing compliance, spanning NDAs, 510(k)s, de novo requests, and PMAs.
• Manufacturing Services ISO 13485:2016 certified manufacturing through the Ubio partner facility in India, approved by CDSCO for diagnostic device manufacture, with a DSIR-approved R&D division in India.
• Smart Tests Colorimetry Enhancement technology that augments paper-based immunoassays (P-ELISA, LFA, μPAD) with quantitation capabilities, photometry, autonomous fluidic circuits, and connected features for meta-analysis, performance feedback, and results sharing.

Quantifiable outcome

• 60% clinical pregnancy rate observed in pilot trial using NICS on 413 embryos
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature6 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Zouves Foundation for Reproductive Medicine (ZFRM)coreStrategic or Co-development Partner · 1 July 2020Partnership with San Francisco-based Zouves Foundation for Reproductive Medicine for co-development of pooled COVID-19 diagnostic testing. The partnership developed a pooled testing protocol that offers 90% reduction in testing cost per patient while maintaining RT-PCR gold standard accuracy.
• PhosphorusminorStrategic or Co-development Partner · 1 June 2020Phosphorus is a ROSA affiliate that received FDA approval for a lab-based PCR test for SARS-CoV-2 (at-home saliva test).
• Avrio GeneticscoreStrategic or Co-development Partner · 1 July 2019Avrio Genetics provides the MALBAC amplification technology powering ROSA Fertility's NICS (Non-Invasive Chromosomal Screening) service. NICS is described as 'powered by Avrio Genetics' and is positioned as best-in-class preimplantation genetic testing.

Scale indicators6 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Natera: Natera is the market-leading provider of preimplantation genetic testing (Spectrum PGT-A) used by IVF clinics. Like ROSA's NICS offering, Natera provides non-invasive and biopsy-based PGT-A on CLIA-certified infrastructure, making it the most direct competitor in IVF embryo aneuploidy screening.
• Olink: Olink provides proximity extension assay-based multiplexed proteomics (Olink Explore, Target) used by pharma and academic researchers for biomarker discovery. It is a direct technological peer to ROSA's proteogenomics / multiplex analyte detection business.
• SomaLogic: SomaLogic operates the SomaScan multiplexed proteomics platform measuring thousands of proteins simultaneously, pursuing biomarker discovery and pharma partnerships. It is a direct technology comparator to ROSA's massively parallel analyte detection platform built around proteomics.
• Igenomix: Igenomix (part of Vitrolife) specializes in reproductive genetics including PGT-A, NIPT, and endometrial receptivity. It is a direct competitor to ROSA Fertility NICS in the IVF/embryo chromosomal screening market.
• Meso Scale Diagnostics: Meso Scale Diagnostics (MSD) develops multiplexed electrochemiluminescence immunoassays measuring multiple analytes per sample. Its platform overlaps directly with ROSA's massively parallel analyte detection feature and serves similar pharma/biomarker discovery customers.

Others

• Recursion Pharmaceuticals: Recursion applies AI/ML to multi-omic datasets to drive drug discovery with pharma partners. While Recursion focuses on therapeutics rather than diagnostics, its ML-driven interpretation of complex biological datasets is thematically comparable to ROSA's computational biology + ML approach to complex disease biomarker discovery.

Emerging players

• AbCellera: AbCellera runs an antibody discovery platform (including a proprietary antibody library) and partners with pharma on biologic programs. Comparable to ROSA's antibody core/repository strategy and its B2B R&D partnership model with biopharma customers.
• Nautilus Biotechnology: Nautilus is building a next-generation proteomics platform aimed at characterizing the entire proteome per sample. It is comparable to ROSA's vision of on-demand, multiplexed diagnostics powered by high-content protein measurements.

Broad incumbents

• NeoGenomics: NeoGenomics operates CLIA-certified labs providing oncology and rare disease genetic/molecular diagnostic services to clinicians and pharma. It is comparable as a CLIA-certified diagnostic testing services business pursuing companion diagnostic partnerships with pharma.
• CooperSurgical: CooperSurgical acquired CooperGenomics, one of the largest PGT-A and reproductive genetics labs in the US. It offers direct PGT-A services that compete with ROSA's NICS franchise and serves the same fertility clinic customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/RosaScientific

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ROSA Scientific